Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: A randomized trial

Chest

Volumn 144, Issue 4, 2013, Pages 1222-1229

  Woodcock, Ashley ^a   Bleecker, Eugene R ^b   Lötvall, Jan ^c   O'Byrne, Paul M ^d   Bateman, Eric D ^e   Medley, Hilary ^f   Ellsworth, Anna ^g   Jacques, Loretta ^f   Busse, William W ^h  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f GLAXOSMITHKLINE   (United Kingdom)

^g GLAXOSMITHKLINE   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; HYDROCORTISONE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BACKACHE; CHOLELITHIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE CONTROL; DISEASE EXACERBATION; DISORIENTATION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; EVENING DOSAGE; FEMALE; FEVER; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYDROCORTISONE URINE LEVEL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; URINARY TRACT INFECTION;

EID: 84885152829     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0178     Document Type: Article

References (24)

1. National Institutes of Health. Guidelines for the diagnosis and management of asthma (EPR-3) 2007.NIH publication 08-4051. National Heart, Lung, and Blood Institute website. http://www.nhlbi.nih.gov/guidelines/asthma/index. htm. Accessed July 12, 2013.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. Global Initiative for Asthma website. http://www.ginasthma.org/ guidelines-gina-report-global-strategyfor- asthma.html. Updated 2012.Accessed July 12, 2013.
3. Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev. 2005;(4): CD005533.
4. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax. 2005; 60 (9): 730-734.
5. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010 ;(5): CD005535.
6. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus bid dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010; 10: 1.
7. Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012; 106 (5): 642-650.
8. Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol. 2012 ;109(5): 353-358.
9. Busse W, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012; 67 (1): 35-41.
10. Lötvall J, Bateman ED, Bleecker ER, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J. 2012; 40(3): 570-579.
11. Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Societyrecommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest. 2010; 137 (1): 138-145.
12. Advair Diskus prescribing information (FP/SAL). GlaxoSmithKline website. http://us.gsk.com/products/assets/us-advair.pdf. Accessed July 12, 2013.
13. Seretide Accuhaler/Seretide Evohaler prescribing information (FP/SAL). GlaxoSmithKline website. http://public.gsk.co.uk/products/seretide.html. Accessed January 15, 2013.
14. Navaratnam P, Friedman HS, Urdaneta E. Treatment with inhaled mometasone furoate reduces short-acting b (2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. Value Health. 2011; 14(2): 339-346.
15. Friedman HS, Navaratnam P, McLaughlin J. Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma. J Asthma. 2010; 47 (9): 994-1000.
16. Jentzsch NS, Camargos P, Sarinho ES, Bousquet J. Adherence rate to beclomethasone dipropionate and the level of asthma control. Respir Med. 2012; 106 (3): 338-343.
17. Guest JF, Davie AM, Ruiz FJ, Greener MJ. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J. 2005; 14 (2): 88-98.
18. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994; 47 (1): 81-87.
19. Sterling R, Lim J, Frith L, Snowise NG, Jacques L, Haumann B. Efficacy and optimal dosing interval of the long-acting beta 2 agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med. 2012; 106 (8): 1110-1115.
20. Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med. 2004; 170 (9): 960-966.
21. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999; 159 (9): 941-955.
22. Serevent Diskus (salmeterol) prescribing information. GlaxoSmithKline website. http://us.gsk.com/products/assets/us-serevent-diskus.pdf. Accessed July 12, 2013.
23. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009; 15 (6): e22-e33.
24. Salford Lung Study website. http://www.salfordlungstudy. co.uk/. Accessed July 12, 2013.